COVID-19 vaccine Nuvaxovid: temporary authorisation from 12 years of age and as booster
Bern, 2.9.2022 - On 6 July 2022, Future Health Pharma GmbH applied to Swissmedic for an indication extension for the vaccine from 12-18 years and authorisation for the booster. The Swiss Agency for Therapeutic Products has assessed both applications positively.